CGT therapy: commercialization in China is imminent

Approved gene therapy products in major global pharmaceutical markets (2015-2022Q1, US, Europe, China, Japan), and Yuanbi Mapping

Gene Therapy Industry Rising in China

Cell gene therapy and gene editing therapy, as a new type of biotechnology, are currently being explored and applied by innovative pharmaceutical companies, R&D institutions, and universities at home and abro.

The price of akirenzai injection in the Chinese market is 2 million yuan

On June 22, 2021, the China National Medical Products Administration (NMPA) approved the launch of Fosun Kite's new CAR-T cell therapy drug Yijilirenxai Injection (also known as Akiloxet, R&D code: FKC87

The pricing of CAR-T cell therapy products is based on comprehensive consideration of various factors such as value, efficacy, and co.

On May 13, 2022 , Fosun Pharma Industry and Kite Pharma signed the "Amendment to the Joint Venture Contract (Eleven.

Previously at the American Blood Annual Meeting in December 2021, the 5-year update data of Gilead's ZUMA-1 study showed that the 5-year overall survival (OS) rate of patients treated with Yescarta reached 46%; among the patients who survived at 5 years, 92% No additional anticancer therapy is requir.

2021 is the first year of commercialization of cell therapy in China

WuXi Junuo, fiscal year 2021: The core CAR-T product Benoda’s revenue was 38 million yuan, with a gross profit margin of 24%; R&D expenses were 414 million yuan, an increase of 84% year-on-ye.

2021 is the first year for the commercialization of cell therapy in Chi.

Complex cell therapy production and manufacturing system: In June 2020, the company's new commercial production base in Suzhou obtained a drug production license from the relevant departments in Jiangsu Provin.

WuXi Junuo pipeline

Attaches great importance to the Chinese market, AAV gene therapy drug Zolgensma enters clinical

Recently, Novartis' blockbuster new gene therapy drug for SMA, Zolgensma (OAV101 injection), launched a Phase III clinical trial for the first time in Chi.

Zolgensma currently sells for $125 million in the.

2022Q1 Novartis Product Performance

This article is only used to provide scientific information to medical and health professionals and does not represent the platform's position

refer to:

NMPA/CDE;

Yaorong Cloud Data,Cloud Data,FDA/EMA;

Public disclosure of relevant companies;

Fosun Pharma;

Fosun Kite, http:// Kite, http:// WuXi Juuo,Juuo,Gilead and other official websites;

https:// survival-data-from-pivotal-study-showing-durable-long-term-survival-in-patients-with-refract;

Price/revenue of 7 CAR-Ts listed globally: the most expensive is US$470,000/needle;

https:// patients-sma-type-2;

and so .